Bialostockie Centrum Onkologii Im. Marii Sklodowskiej-Curie W Bialymstoku

The Bialostockie Centrum Onkologii Im. Marii Sklodowskiej-Curie W Bialymstoku is running a broad range of oncology studies focused on major solid tumors, especially breast cancer, ovarian cancer, endometrial cancer, lung cancer, and urothelial cancer. These trials are designed to test new treatment options, compare them with current standard care, and improve outcomes for people with advanced or early-stage disease.

• Research in breast cancer includes hormone receptor-positive, HER2-negative, HER2-positive, and triple-negative disease, with studies aiming to improve treatment effectiveness and reduce recurrence.
• Gynecologic cancers such as ovarian, endometrial, cervical, and fallopian tube cancer are a major focus, with trials evaluating new therapies for recurrent, metastatic, and high-risk disease.
• Several studies in lung cancer, gastric cancer, and biliary tract cancer are assessing whether newer immunotherapy- and antibody-based approaches can improve survival.

The site’s oncology program also includes trials in colorectal cancer, prostate cancer, bladder cancer, and nasopharyngeal cancer, reflecting a strong interest in both treatment innovation and better disease control across a wide spectrum of cancers.

This research area at Oddział Onkologii Klinicznej im. dr E. Pileckiej z pododdziałem Chemioterapii Dziennej centers on cancers affecting the female reproductive and urinary systems, with a strong emphasis on ovarian cancer, endometrial cancer, cervical cancer, and related advanced gynecologic tumors. The studies aim to find better ways to treat hard-to-manage disease, delay progression, and support longer-lasting responses.

• Ovarian cancer trials include platinum-sensitive, platinum-resistant, recurrent, and high-grade serous disease, with a focus on improving control after standard treatment.
• Endometrial cancer studies are examining new approaches for recurrent, metastatic, and primary advanced disease, including options for patients with specific tumor features.
• Cervical cancer research is evaluating treatments for locally advanced and recurrent disease to improve effectiveness in later lines of therapy.

There is also growing interest in urothelial cancer and other urinary tract tumors, where trials are looking for more effective strategies for advanced or unresectable disease.

Some studies at the site span multiple tumor types and do not fit neatly into a single disease category. These trials often focus on broader questions in cancer care, such as whether a new therapy can improve survival, delay relapse, or work better than the current standard treatment across different solid tumors.

• Research includes immunotherapy, antibody-drug conjugates, and other targeted cancer treatments across several cancer types.
• Some trials are designed to support patients who are already benefiting from treatment, with ongoing monitoring of safety and tolerability.
• Diagnostic research is also represented, including studies that aim to improve prostate cancer staging and lesion detection.

Overall, this reflects a versatile clinical trial portfolio at the Bialystok Cancer Center, combining treatment development, comparative effectiveness research, and diagnostic innovation.